Drug Details

General Information of the Drug (ID: DR7498)
Name
Sulfamethoxazole
Synonyms
sulfamethoxazole; 723-46-6; Sulphamethoxazole; Gantanol; Sulfisomezole; Sulfamethoxazol; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; Metoxal; Sulfamethylisoxazole; Simsinomin; Radonil; Sinomin; Sulphamethoxazol; Sulpha-methoxizole; Bactrim; Sulfamethalazole; Azo-gantanol; 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide; Sulphamethylisoxazole; Urobak; Ro 4-2130; 3-Sulfanilamido-5-methylisoxazole; Gantanol-DS; Sulphisomezole; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; 5-Methyl-3-sulfanilamidoisoxazole; MS 53; 3-Sulphanilamido-5-methylisoxazole; Benzenesulfonamide, 4-amino-N-(5-methyl-3-isoxazolyl)-; 5-Methyl-3-sulphanil-amidoisoxazole; 3-(p-Aminophenylsulfonamido)-5-methylisoxazole; 5-Methyl-3-sulfanylamidoisoxazole; N'-(5-Methyl-3-isoxazolyl)sulfanilamide; N1-(5-Methyl-3-isoxazolyl)sulfanilamide; N'-(5-Methylisoxazol-3-yl)sulphanilamide; 3-(para-Aminophenylsulphonamido)-5-methylisoxazole; Sulfamethoxazole-d4; Sulmeprim; Trimeth/Sulfa; A047; SMX; Sulfamethoxazole sodium; UNII-JE42381TNV; N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide; CHEBI:9332; N'-(5-Methyl-3-isoxazole)sulfanilamide; Sulfamethoxizole; Ro 6-2580/11; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide; Sulfanilamide, N'-(5-methyl-3-isoxazolyl)-; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)-; 4-AMINO-N-(5-METHYL-3-ISOXAZOYL)BENZENESULFONAMIDE; Sulfametoxazol; Bactrimel; Gamazole; MFCD00010546; CHEMBL443; N1-(5-Methylisoxazol-3-yl)sulfanilamide; MLS000069732; JE42381TNV; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzene-1-sulfonamide; Solfametossazolo; N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide; 5-Methyl-3-sulfonylamidoisoxazole; STX-608; Sulfamethoxazolum; NSC147832; 4-Amino-N-(5-methyl-3-isoxazolyl)-benzenesulfonamide; NSC-147832; NCGC00016533-05; NCGC00186654-01; CAS-723-46-6; SMR000058223; DSSTox_CID_6064; Solfametossazolo [DCIT]; 3-(p-Aminobenzenesulfonamido)-5-methylisoxazole; DSSTox_RID_78001; DSSTox_GSID_26064; [(4-aminophenyl)sulfonyl](5-methylisoxazol-3-yl)amine; Sulfametoxazol [INN-Spanish]; Sulfamethoxazolum [INN-Latin]; CCRIS 567; HSDB 3186; SR-01000000217; EINECS 211-963-3; NSC 147832; BRN 0226453; N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide; Sulfanilamide, N(1)-(5-methyl-3-isoxazolyl)-; 08D; Prestwick_453; ALBB-002089; Septran (Salt/Mix); Septrin (Salt/Mix); Sulfamethoxazole,(S); Eusaprim (Salt/Mix); Ro-4-2130; Spectrum_000994; Sulfamethoxazole(USAN); Sulfamethoxazole-13C6; Opera_ID_882; Maybridge1_007190; Prestwick0_000177; Prestwick1_000177; Prestwick2_000177; Prestwick3_000177; Spectrum2_000788; Spectrum3_000584; Spectrum4_000345; Spectrum5_000982; Sulfamethoxazole [USAN:USP:INN:BAN:JAN]; Epitope ID:114999; Co-trimoxazole (Salt/Mix); SCHEMBL3656; Oprea1_114486; Oprea1_285680; BSPBio_000073; BSPBio_002028; KBioGR_000749; KBioSS_001474; MLS001055354; MLS001074165; MLS006011871; BIDD:GT0731; DivK1c_000649; SPECTRUM1500550; SPBio_000896; SPBio_001994; ARONIS018156; BPBio1_000081; DTXSID8026064; component of Bactrim (Salt/Mix); GTPL10933; HMS502A11; HMS561O18; JLKIGFTWXXRPMT-UHFFFAOYSA-; KBio1_000649; KBio2_001474; KBio2_004042; KBio2_006610; KBio3_001528; ZINC89763; EBD3403; N1-(5-methylisoxazol-3-yl)-4-aminobenzene-1-sulfonamide; WLN: T5NOJ C1 EMSWR DZ; NINDS_000649; HMS1568D15; HMS1921A21; HMS2092K03; HMS2095D15; HMS2233L13; HMS3259E06; HMS3372M22; HMS3655O22; HMS3712D15; Pharmakon1600-01500550; BCP02881; HY-B0322; Sulfamethoxazole (JP17/USP/INN); Sulfamethoxazole, analytical standard; Tox21_110480; Tox21_200353; ANW-43073; BBL004554; BDBM50029770; CCG-40166; HTS001394; KM1475; NSC757328; Ro-42130; s1915; SBB057675; SBB071655; STK007988; AKOS000200952; component of Azo Gantanol (Salt/Mix); Tox21_110480_1; BS-3542; DB01015; MCULE-1450176600; NC00537; NSC-757328; RP-2145; IDI1_000649; NCGC00016533-01; NCGC00016533-02; NCGC00016533-03; NCGC00016533-04; NCGC00016533-06; NCGC00016533-07; NCGC00016533-08; NCGC00016533-09; NCGC00016533-10; NCGC00016533-11; NCGC00016533-12; NCGC00016533-14; NCGC00021995-03; NCGC00021995-04; NCGC00021995-05; NCGC00257907-01; AC-11118; AK-36221; H463; ST024740; SY018888; BCP0726000283; N'-(5-Methyl-3-isoxazolyl)-Sulfanilamide; N1-(5-methyl-3-isoxazolyl)-Sulfanilamide; N1-(5-Methyl-3-isoxazolyl)sulphanilamide; SBI-0051524.P003; DB-055629; AB00052099; BB 0242379; FT-0602616; N^1-(5-Methyl-3-isoxazolyl)-Sulfanilamide; ST51006798; SW196670-3; C07315; D00447; J10090; Sulfamethoxazole 100 microg/mL in Acetonitrile; AB00052099-14; AB00052099-16; AB00052099_17; AB00052099_18; Ndimethyl1-(5-methyl-3-isoxazolyl)-Sulfanilamide; Q415843; Q-201762; SR-01000000217-2; SR-01000000217-3; Sulfamethoxazole, VETRANAL(TM), analytical standard; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)- (8CI); 4-Amino-N-(5-methylisoxazol-3-yl)benzenesulphonamide; BRD-K28494619-001-05-0; BRD-K28494619-001-15-9; BRD-K28494619-001-26-6; Z57198677; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzene sulfonamide; Sulfamethoxazole, British Pharmacopoeia (BP) Reference Standard; Sulfamethoxazole, certified reference material, TraceCERT(R); 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; SMX; SMZ; Sulfamethoxazole, European Pharmacopoeia (EP) Reference Standard; Sulfamethoxazole, United States Pharmacopeia (USP) Reference Standard; Sulfamethoxazole, Pharmaceutical Secondary Standard; Certified Reference Material; 129378-89-8
    Click to Show/Hide
Molecular Type
Small molecule
Disease Bacterial infection [ICD-11: 1A00-1C4Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C10H11N3O3S
PubChem CID
5329
Canonical SMILES
CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N
InChI
1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)
InChIKey
JLKIGFTWXXRPMT-UHFFFAOYSA-N
CAS Number
CAS 723-46-6
ChEBI ID
CHEBI:9332
TTD Drug ID
D0R9OH
DrugBank ID
DB01015
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Selenium      Soil     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model This experiment was carried out on 30 Wistar rats weighing 100-125 g, liver cancer was induced by a carcinogenic dose of 200 mg/kg body weight, I.P. DENA when associated with fasting/refeeding.
                    Experimental
                    Result(s)		 Selenium and sulfonamide (sulfamethoxazole) together can possess synergistic chemopreventive action.
Target and Pathway
Target(s) Bacterial Dihydropteroate synthetase (Bact folP)  Molecule Info  [3]
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Reference 2 Combination of sulfamethoxazole and selenium in anticancer therapy: a novel approach. Mol Cell Biochem. 2013 Dec;384(1-2):279-85.
Reference 3 In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother. 1995 Apr;39(4):948-52.
 Download Picture         KEGG Link